Novo Nordisk A/S $NVO Shares Sold by Baldwin Wealth Partners LLC MA

Key Points

• Baldwin Wealth Partners cut its Novo Nordisk stake by 82.0% in Q3, selling 148,569 shares and leaving 32,556 shares worth about $1.81 million at quarter-end.
• Novo has **filed an NDA for once‑weekly CagriSema** and is pursuing a higher 7.2 mg dose of Wegovy—both developments that could materially boost its obesity franchise if approved and commercialized effectively.
• Analyst sentiment is mixed: MarketBeat shows a consensus rating of "Hold" with a $53.33 target, based on 1 Strong Buy, 6 Buy, 11 Hold and 4 Sell ratings.

Baldwin Wealth Partners LLC MA lessened its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 82.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 32,556 shares of the company's stock after selling 148,569 shares during the period. Baldwin Wealth Partners LLC MA's holdings in Novo Nordisk A/S were worth $1,807,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of NVO. NewSquare Capital LLC grew its holdings in Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company's stock valued at $31,000 after buying an additional 282 shares during the last quarter. Mid American Wealth Advisory Group Inc. acquired a new position in shares of Novo Nordisk A/S in the second quarter worth $37,000. State of Wyoming purchased a new stake in shares of Novo Nordisk A/S in the first quarter valued at $38,000. Maseco LLP acquired a new stake in shares of Novo Nordisk A/S during the second quarter valued at $39,000. Finally, Copeland Capital Management LLC boosted its stake in shares of Novo Nordisk A/S by 47.3% during the second quarter. Copeland Capital Management LLC now owns 579 shares of the company's stock valued at $40,000 after acquiring an additional 186 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on NVO shares. Sanford C. Bernstein raised shares of Novo Nordisk A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, September 9th. Morgan Stanley reissued an "underweight" rating and issued a $42.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, December 3rd. The Goldman Sachs Group reduced their price objective on shares of Novo Nordisk A/S from $60.00 to $54.00 and set a "buy" rating on the stock in a research note on Friday, November 28th. Rothschild Redb raised shares of Novo Nordisk A/S from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 16th. Finally, HSBC reiterated a "hold" rating and issued a $54.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have assigned a Hold rating and four have issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $53.33.

Novo Nordisk A/S Trading Up 1.0%

Shares of NVO opened at $48.10 on Monday. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $93.80. The firm has a market capitalization of $214.76 billion, a P/E ratio of 13.98 and a beta of 0.67. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. The stock's fifty day simple moving average is $49.84 and its 200 day simple moving average is $57.49.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.77 by $0.25. The firm had revenue of $11.79 billion during the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo filed an NDA with the U.S. FDA for once‑weekly CagriSema, a next‑generation combination obesity injection that showed superior Phase III weight‑loss results — a potential major booster to its obesity franchise if approved. Article Title
• Positive Sentiment: Novo is pursuing a higher 7.2 mg Wegovy dose after data showed stronger weight loss — this could help reclaim share versus rivals (e.g., Eli Lilly’s Zepbound) if approved and commercialized effectively. Article Title
• Positive Sentiment: Analyst/commentary pieces highlight upside from oral Wegovy development, supply‑chain fixes and restructuring that could materially improve margins and growth if execution continues. Article Title
• Positive Sentiment: Kepler Capital initiated/maintained a buy view (reported coverage), giving some buy‑side support to the shares. Article Title
• Neutral Sentiment: UBS reiterated a Neutral (Hold) rating and left its price target unchanged, signaling continued caution on competitive pressures despite product progress. Article Title
• Neutral Sentiment: Commentary pieces are reassessing Novo’s valuation after a steep, year‑long share decline; some see a longer runway to recovery while others point to durable competitive threats. Article Title
• Negative Sentiment: Novo issued profit warnings and underwent a CEO change earlier this year and cut guidance, contributing to a large YTD share decline; that operational uncertainty remains a drag on investor confidence. Article Title
• Negative Sentiment: Shares recently dipped more than the broader market after earnings/profitability concerns were flagged; short‑term volatility is likely to persist as investors weigh approvals vs competitive share losses. Article Title

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company's core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.